ASCO 2026: Key Oncology Data Readouts to Watch

Key Takeaways

• The ASCO 2026 Annual Meeting will be held in Chicago from May 29 to June 2.
• Late-breaking abstracts (LBAs) will be released on May 21, 2026, and on presentation days.
• Key Phase 3 trial data will be presented across various cancers, including liver cancer, multiple myeloma, prostate cancer, lymphoma, NSCLC, and uveal melanoma.

The 2026 ASCO Annual Meeting, scheduled for May 29 – June 2 in Chicago, will feature critical data readouts impacting the oncology landscape. With the release of late-breaking abstracts (LBAs) on May 21, and further releases on presentation days, the meeting promises to highlight the latest advancements in cancer research and treatment.

The ASCO Annual Meeting is a premier event for oncology professionals, offering a platform to discuss cutting-edge research, innovative treatments, and collaborative strategies to improve patient outcomes. The 2026 meeting will likely draw significant attention due to the presentation of late-breaking abstracts featuring Phase 3 trial data across a spectrum of cancer types.

Late-Breaking Abstract Highlights

Several late-breaking abstracts are anticipated to draw considerable interest:

• Telix Pharmaceuticals: Data from the ProstACT Global Phase 3 trial (Part 1) (LBA5009) focusing on the safety and tolerability of prostate cancer radiopharmaceutical therapy. This will be presented as a late-breaking oral presentation on June 1, from 3:12–3:24 PM CDT in the Arie Crown Theater, within the Clinical Science Symposium – Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer.
• IDEAYA Biosciences: Complete data from the OptimUM-02 Phase 2/3 registrational trial (LBA9503) evaluating darovasertib in combination with crizotinib as a first-line treatment for HLA*A2-negative metastatic uveal melanoma. The late-breaking oral presentation is scheduled for June 1, 8–11 AM during the Oral Abstract Session, Melanoma/Skin Cancers.
• Dizal Pharmaceutical: Data from the WU-KONG28 pivotal Phase 3 trial of ZEGFROVY® (sunvozertinib) in NSCLC. The oral presentation details and abstract number are to be announced.
• Pfizer: Presentation of data from the TALAPRO-3 Phase 3 trial (LBA5007), highlighting rPFS benefit in oncology, as part of Pfizer's broader presentation of over 40 abstracts.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for oncology. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Key Data Readouts from Pfizer

Pfizer is set to present data from over 40 abstracts, including three late-breaking sessions and eight oral/rapid oral presentations. Key highlights include:

• Sigvotatug vedotin (SV) + pembrolizumab: Updated phase 1 results (SGNB6A-001) will be presented in a poster session (Abstract 8522) on May 31, from 9:00 AM-12:00 PM CDT. This presentation will cover sigvotatug vedotin (investigational integrin beta-6 ADC) in combination with pembrolizumab for lung cancer.
• PF-08046054 (PDL1V): Phase 1 data on ctDNA reduction correlating with response and PD-L1 expression in NSCLC will be shared via poster (Abstract 8609) on May 31, from 9:00 AM-12:00 PM CDT.
• Palbociclib + tamoxifen ± goserelin: Final overall survival (OS) analysis from the PATHWAY phase 3 trial (LBA1018) in HR+/HER2- breast cancer will be presented as a rapid oral presentation on May 31, from 11:30 AM-1:00 PM CDT.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Additional Data to Watch

In addition to the highlighted presentations, several other key data readouts are anticipated:

• AstraZeneca: Data from the Emerald-3 trial (LBA4000) evaluating durvalumab (Imfinzi) + tremelimumab (Imjudo) in liver cancer, demonstrating a PFS benefit in cohort 1.
• Bristol Myers Squibb: Results from the Successor-2 trial (LBA7506) of mezigdomide in multiple myeloma, showing positive PFS data.
• Incyte: Data from the Frontmind trial (LBA7000) of tafasitamab (Monjuvi) in lymphoma, with positive topline results.
• Karyopharm: Data from the Sentry trial (LBA6500) of selinexor (Xpovio) in myelofibrosis, focusing on spleen volume, symptom reduction, and OS/tolerability data.

Frequently Asked Questions

1. What is the ASCO Annual Meeting?

   The ASCO Annual Meeting is a major oncology conference where researchers, clinicians, and industry professionals gather to discuss the latest advancements in cancer research and treatment.

2. When and where will ASCO 2026 take place?

   ASCO 2026 will be held from May 29 to June 2 in Chicago, IL.

3. When will the late-breaking abstracts be released?

   Most abstracts will be released online on May 21, 2026, at 5 PM ET. Late-breaking abstracts (LBAs) will be released at 7 AM CDT/8 AM ET on the day of their presentation.

4. What types of cancer are highlighted in the late-breaking abstracts?

   The late-breaking abstracts feature data across a variety of cancers, including liver cancer, multiple myeloma, prostate cancer, lymphoma, NSCLC, and uveal melanoma.

5. Which companies are presenting key data at ASCO 2026?

   Key companies presenting data include Telix Pharmaceuticals, IDEAYA Biosciences, Dizal Pharmaceutical, Pfizer, AstraZeneca, Bristol Myers Squibb, Incyte, and Karyopharm.

References

1. Pfizer Showcases Oncology Innovation and Next-Generation Medicines at ASCO 2026. Pfizer Press Release.
2. ProstACT Global Phase 3 Part 1 Selected as Late-Breaking Abstract at ASCO 2026. BioSpace Press Release.
3. Join the Conversations to Improve Tomorrow’s Outcomes at the 2026 ASCO Annual Meeting. ASCO Connection.
4. Dizal to Report Key Progress in Its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026. PR Newswire.
5. ASCO 2026 Preview: Revolution Completes Its Rout. OncologyPipeline.
6. IDEAYA Biosciences to Present Complete Data from the OptimUM-02 Phase 2/3 Registrational Trial of Darovasertib (PKC Inhibitor) in 1L Metastatic Uveal Melanoma at ASCO 2026. IDEAYA Biosciences Press Release.

Related coverage

• Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• Cardiff Oncology pipeline update: onvansertib trials, FDA meeting, and catalysts